SML0408
羧酰氨基三唑
≥98% (HPLC)
别名:
5-氨基-1-(3,5-二氯-4-(4-氯苯甲酰基)苄基甲基)-1H-1,2,3-三氮唑-4-羧酰胺, CAI, L-651582
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C17H12Cl3N5O2
化学文摘社编号:
分子量:
424.67
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL (clear solution)
storage temp.
2-8°C
SMILES string
NC(=O)c1nnn(Cc2cc(Cl)c(c(Cl)c2)C(=O)c3ccc(Cl)cc3)c1N
InChI
1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
InChI key
WNRZHQBJSXRYJK-UHFFFAOYSA-N
Biochem/physiol Actions
羧胺三唑（CAI）是一种没有细胞毒性的抗癌药物。它具有抗炎特性，并减少促炎细胞因子的释放。CAI可以在体外和体内阻止多种人类癌细胞和内皮细胞的增殖和侵袭行为。它可用于治疗多种急性和慢性炎症模型，如佐剂性关节炎和炎症性肠病（IBD）。CAI在体外阻断肿瘤细胞增殖并刺激细胞凋亡。
羧酰氨基三唑是一种钙通道阻滞剂/钙通量抑制剂；阻断 CRAC 通道功能。
羧酰氨基三唑（L-651582）是一种口服活性钙通道阻滞剂。羧酰氨基三唑阻断细胞内和线粒体钙的进入和通量，从而抑制细胞增殖、激活钙释放激活的钙通道（CRAC）功能并维持线粒体膜电位。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
商品
我们提供多种与钙通道相关的产品以满足您的各类研究需求。
We offers many products related to calcium channels for your research needs.
Lars P J Cruysberg et al.
Retina (Philadelphia, Pa.), 25(8), 1022-1031 (2005-12-13)
To evaluate the human transscleral diffusion and intravitreal delivery of carboxyamido-triazole (CAI) and 2-Methoxyestradiol (2ME2). The transscleral diffusion of two retinal antiangiogenic molecules, CAI and 2ME2, was measured in vitro to assess their potential transscleral delivery. Varying concentrations and different
Kevin Deschamps et al.
Clinical biomechanics (Bristol, Avon), 54, 1-7 (2018-03-05)
Investigate differences in multi-segment foot kinematics between controls and participants with chronic ankle instability during running with a midfoot striking pattern and to evaluate the effect of Low-Dye and High-Dye taping. Three-dimensional multi-segment foot kinematics of 12 controls and 15
Walter M Stadler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(16), 3726-3732 (2005-06-01)
To assess the disease-stabilizing activity of carboxyaminoimidazole (CAI) in patients with metastatic renal cell cancer (RCC) using a randomized discontinuation trial (RDT) design. Recruited patients had a performance status of 0 to 2, minimal neuropathy or cerebellar dysfunction, measurable disease
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0408-25MG | 04061832962948 |
| SML0408-5MG | 04061832962955 |